Strengthening Partnerships: Mochida Pharmaceuticals Visits Shannon HQ to discuss 2025 Collaborative Projects The Mochida Pharmaceuticals leadership, quality and regulatory teams visited our headquarters in Shannon, Ireland this month, to discuss collaborative development projects for 2025 and beyond. We are pleased to share that the future is bright, with projects planned for trauma, tendon & ligament, as well as cavernous nerve. Pictured below is our Managing Partner, Paul Burke and Chief Science Officer, Gerard Insley presenting Hitoshi Mizuno, Head of Biomaterials business Division at Mochida Pharmaceuticals Ltd, with a plaque to mark the successful launch of ReFeel Nerve Repair Solution ‘Le Cheile’. #mochidapharamceuticals #ReFeelnerverepairsolution #acceleratingmedicalinnovation #partners

A special moment for our operations and manufacturing team last week, as they prepared the first commercial shipment of ReFeel Nerve Repair Solution for dispatch. After four years of manufacturing process setup, testing and small-scale production for pre-clinical studies, the first batch is now on its way to the US to be used in patients for the first time. Congratulations to this team and to our partners Mochida Pharmaceutical Co. Ltd., on all they have accomplished so far. Together, we have successfully developed and launched a technology that is truly #innovative and will enhance the well-being of patients. #commerciallaunch #acceleratingmedicalinnovation #pbcbiomed #ReFeelnerverepairsolution

PBC Biomed Inc welcomed the Mochida team to their Epicenter office in Memphis last week, ahead of the ReFeel Nerve Repair Solution launch.